Mouse model could ID mental illness gene
09 July, 2003 by Melissa TrudingerA schizophrenic mouse model has led the way to identification of a gene potentially predisposing humans to the devastating human mental illness.
Huntington's test tale proves our unpredictability
08 July, 2003 by Graeme O'NeillWithin a year of the identification in 1993 of the huntingtin gene, which in mutant form causes the fatal brain disorder Huntington's disease, geneticists devised a test to detect the mutation, and offered it to families with a history of the disease.
Granny off the hook in menopause mystery
07 July, 2003 by Graeme O'NeillGeneticists appear to have failed in their latest attempt to indict human grandmothers in the court of life for indirectly visiting menopause upon their daughters.
Garvan reaps surprise windfall
20 June, 2003 by Jeremy TorrThe Garvan Institute celebrated 40 years of sharp end research into cancer and associated diseases last week -- and in the process gained over $1million in research funds.
Norwood Abbey planning clinical trial
19 June, 2003 by Melissa TrudingerNorwood Abbey is in the midst of planning an international clinical trial examining the use of its Gonadotropin Releasing Hormone (GnRH) analogue drugs to revive the immune system in patients with HIV/AIDS.
Aust HIV vaccine trial now recruiting subjects
06 June, 2003 by Jeremy TorrThe first HIV vaccine developed in Australia is expected to go to clinical trials within months, with results expected in mid 2004.
Woolcock, Hunter join forces in sleep research network
04 June, 2003 by Susan WilliamsonThe Woolcock Institute of Medical Research in Sydney and the Hunter Medical Research Institute (HMRI) in Newcastle have joined forces to form what they claim is the largest respiratory and sleep research network in the southern hemisphere.
Tailoring chemotherapy to specific cancer cells
03 June, 2003 by Susan WilliamsonAs part of the Australian Society for Medical Research's (ASMR) Medical Research Week, the Amgen Medical Researcher Award was presented today to Dr Ricky Johnstone from Melbourne's Peter MacCallum Cancer Centre.
GTG cleans slate, opens door to new business deals
29 May, 2003 by Melissa TrudingerMelbourne company Genetic Technologies (GTG) has introduced a twist in its licensing strategy by offering companies the chance to be forgiven for past transgressions of GTG's non-coding DNA patents.
EvoGenix swaps dreams for reality with Start grant
29 May, 2003 by Jeremy TorrEvoGenix has won $900,000 from the latest round of federal government R&D Start grant awards, adding a major boost to its R&D program over the next two years.
Cytopia claims success in early-stage anti-cancer drug trial
28 May, 2003 by Melissa TrudingerMelbourne drug discovery company Cytopia has claimed its lead anti-cancer compounds were active in vitro against a common form of childhood cancer.
Serendipity strikes cancer cells
19 May, 2003 by Jeremy TorrResearchers at the University of NSW looking for a protein analysis tool have accidentally come up with a drug that can halt cell growth in tumours.
Antisense wins $1.1m Start grant for psoriasis project
19 May, 2003 by Melissa TrudingerMelbourne company Antisense Therapeutics has won a $AUD1.1 million R&D Start grant, in the first round of funding awarded since the Federal government reopened the program late last year.
Euro giant Serono to develop Amrad compound
09 May, 2003 by Melissa TrudingerMelbourne-based Amrad has granted an exclusive license to Swiss/US company Serono to develop and commercialise emfilermin for use in reproductive health indications, under an option in the original partnership between the two companies.
WEHI researchers using stem cells to prevent diabetes
09 May, 2003 by Melissa TrudingerResearchers at the Walter and Eliza Hall Institute are devising a stem-cell-based approach designed to prevent the development of type 1 diabetes in susceptible individuals by engineering the haematopoietic stem cells to express proinsulin after differentiation into antigen presenting cells.
